Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis

Imagem de Miniatura
Arquivos
art_FERREIRA_Assessment_of_TSPAN_Expression_Profile_and_Their_Role_2021.PDF (4.37 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
FERREIRA, Kelly Pedrozo
BAIOCCHI, Glauco
SOARES, Fernando Augusto
ROCHA, Rafael Malagoli
DOBROFF, Andrey Senos
Citação
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.22, n.9, article ID 5015, 22p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The role and prognostic value of tetraspanins (TSPANs) in vulvar squamous cell carcinoma (VSCC) remain poorly understood. We sought to primarily determine, at both the molecular and tissue level, the expression profile of the TSPANs CD9, CD63, CD81, and CD82 in archived VSCC samples (n = 117) and further investigate their clinical relevance as prognostic markers. Our studies led us to identify CD63 as the most highly expressed TSPAN, at the gene and protein levels. Multicomparison studies also revealed that the expression of CD9 was associated with tumor size, whereas CD63 upregulation was associated with histological diagnosis and vascular invasion. Moreover, low expression of CD81 and CD82 was associated with worse prognosis. To determine the role of TSPANs in VSCC at the cellular level, we assessed the mRNA levels of CD63 and CD82 in established metastatic (SW962) and non-metastatic (SW954) VSCC human cell lines. CD82 was found to be downregulated in SW962 cells, thus supporting its metastasis suppressor role. However, CD63 was significantly upregulated in both cell lines. Silencing of CD63 by siRNA led to a significant decrease in proliferation of both SW954 and SW962. Furthermore, in SW962 particularly, CD63-siRNA also remarkably inhibited cell migration. Altogether, our data suggest that the differential expression of TSPANs represents an important feature for prognosis of VSCC patients and indicates that CD63 and CD82 are likely potential therapeutic targets in VSCC.
Palavras-chave
tetraspanins, VSCC, immunohistochemistry, HPV infection, prognosis, cell culture, siRNA
URI
https://observatorio.fm.usp.br/handle/OPI/40764
Referências
  1. Akagi EM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-822
  2. An HJ, 2020, THORAC CANCER, V11, P1989, DOI 10.1111/1759-7714.13492
  3. Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
  4. Baek J, 2019, J BREAST CANCER, V22, P77, DOI 10.4048/jbc.2019.22.e9
  5. Baiocchi G, 2015, EJSO-EUR J SURG ONC, V41, P1653, DOI 10.1016/j.ejso.2015.09.024
  6. Baiocchi G, 2013, EJSO-EUR J SURG ONC, V39, P780, DOI 10.1016/j.ejso.2013.03.004
  7. Baiocchi G, 2013, EJSO-EUR J SURG ONC, V39, P339, DOI 10.1016/j.ejso.2013.02.012
  8. Bizzarri N, 2017, J OBSTET GYNAECOL, V37, P975, DOI 10.1080/01443615.2017.1318269
  9. Carloni V, 2013, ONCOGENE, V32, P2649, DOI 10.1038/onc.2012.268
  10. Carvalho K.C., 2015, J DIS MARKERS, V2, P1024
  11. Buim MEC, 2010, ORAL ONCOL, V46, P166, DOI 10.1016/j.oraloncology.2009.11.009
  12. Chai J, 2017, MOL MED REP, V15, P1527, DOI 10.3892/mmr.2017.6186
  13. Chai J, 2016, ONCOL REP, V36, P737, DOI 10.3892/or.2016.4893
  14. de Almeida BC, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111452
  15. Earnest JT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006546
  16. Fast LA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103007
  17. Garcia-Mayea Y, 2020, CANCERS, V12, DOI 10.3390/cancers12113269
  18. Guidone L.R.M., 2010, THESIS
  19. Hantak MP, 2019, J VIROL, V93, DOI 10.1128/JVI.01429-17
  20. Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
  21. Heo K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030388
  22. Hiroshima K, 2019, EXP CELL RES, V384, DOI 10.1016/j.yexcr.2019.111622
  23. Hong IK, 2006, J BIOL CHEM, V281, P24279, DOI 10.1074/jbc.M601209200
  24. Hori H, 2004, J SURG RES, V117, P208, DOI 10.1016/j.jss.2004.01.014
  25. Huan J, 2015, INT J CLIN EXP PATHO, V8, P3054
  26. Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8
  27. Huang CL, 1997, INT J ONCOL, V11, P1045
  28. IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231
  29. Jee BK, 2006, BIOCHEM BIOPH RES CO, V342, P655, DOI 10.1016/j.bbrc.2006.01.153
  30. Jiang LJ, 2019, CLIN EXP MED, V19, P377, DOI 10.1007/s10238-019-00554-x
  31. Jones EL, 2016, J IMMUNOL, V196, P978, DOI 10.4049/jimmunol.1500357
  32. Kaprio T, 2020, HISTOL HISTOPATHOL, V35, P887, DOI 10.14670/HH-18-209
  33. Kramer F, 2013, GEBURTSH FRAUENHEILK, V73, P142, DOI 10.1055/s-0032-1328133
  34. Kudo K, 2019, FASEB J, V33, P3851, DOI 10.1096/fj.201800664RR
  35. Kumari S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050411
  36. Kussaibi Haitham, 2020, Asian Pac J Cancer Prev, V21, P2549, DOI 10.31557/APJCP.2020.21.9.2549
  37. Kusukawa J, 2001, J ORAL PATHOL MED, V30, P73, DOI 10.1034/j.1600-0714.2001.300202.x
  38. Kwon HJ, 2014, PATHOL RES PRACT, V210, P285, DOI 10.1016/j.prp.2014.01.004
  39. Lang T, 2020, CURR BIOL, V30, pR204, DOI 10.1016/j.cub.2020.01.007
  40. Lavorato-Rocha AM, 2015, METHODS, V77-78, P20, DOI 10.1016/j.ymeth.2014.12.017
  41. Lavorato-Rocha AM, 2016, MOL CANCER RES, V14, P720, DOI 10.1158/1541-7786.MCR-15-0366
  42. Lavorato-Rocha AM, 2013, TUMOR BIOL, V34, P3713, DOI 10.1007/s13277-013-0955-0
  43. Lavorato-Rocha AM, 2013, ANN SURG ONCOL, V20, P31, DOI 10.1245/s10434-012-2560-7
  44. Ma ZK, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/8899924
  45. Maia BD, 2016, ONCOTARGET, V7, P49217, DOI 10.18632/oncotarget.10247
  46. Maia BD, 2014, HUM PATHOL, V45, P917, DOI 10.1016/j.humpath.2014.01.015
  47. Maia BD, 2013, GYNECOL OBSTET INVES, V75, P53, DOI 10.1159/000343758
  48. Maia BD, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-150
  49. Malik FA, 2009, HISTOL HISTOPATHOL, V24, P519, DOI 10.14670/HH-24.519
  50. Mantovani G, 2020, J CANCER RES CLIN, V146, P1647, DOI 10.1007/s00432-020-03226-6
  51. Miyake M, 1996, CANCER RES, V56, P1244
  52. Mizoshiri N, 2019, CELL ONCOL, V42, P861, DOI 10.1007/s13402-019-00472-w
  53. Palisoul ML, 2017, GYNECOL ONCOL, V146, P305, DOI 10.1016/j.ygyno.2017.05.011
  54. Park CS, 2016, ONCOGENE, V35, P4540, DOI 10.1038/onc.2015.520
  55. Pols MS, 2009, EXP CELL RES, V315, P1584, DOI 10.1016/j.yexcr.2008.09.020
  56. Proctor L, 2020, INT J GYNECOL CANCER, V30, P100, DOI 10.1136/ijgc-2019-000793
  57. Protzel C, 2008, VIRCHOWS ARCH, V452, P369, DOI 10.1007/s00428-008-0590-0
  58. Quagliano A, 2020, BLOOD ADV, V4, P4393, DOI 10.1182/bloodadvances.2020001592
  59. Rakislova N, 2020, AM J SURG PATHOL, V44, P1506, DOI 10.1097/PAS.0000000000001540
  60. Rasmussen CL, 2018, INT J CANCER, V142, P1158, DOI 10.1002/ijc.31139
  61. Ridnour LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044081
  62. Robert JMH, 2021, DRUG DISCOV TODAY, V26, P56, DOI 10.1016/j.drudis.2020.10.022
  63. Rodrigues IS, 2013, BRIT J CANCER, V109, P184, DOI 10.1038/bjc.2013.273
  64. Rogers LJ, 2018, INT J GYNECOL OBSTET, V143, P4, DOI 10.1002/ijgo.12609
  65. Saito Y, 2006, CANCER RES, V66, P9557, DOI 10.1158/0008-5472.CAN-06-1131
  66. Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X
  67. Soyuer S, 2010, PATHOL RES PRACT, V206, P607, DOI 10.1016/j.prp.2010.04.004
  68. Spoden G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003313
  69. Tavsan Z, 2020, CELL ADHES MIGR, V14, P57, DOI 10.1080/19336918.2020.1732761
  70. te Grootenhuis NC, 2018, GYNECOL ONCOL, V148, P622, DOI 10.1016/j.ygyno.2017.11.006
  71. Termini CM, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00034
  72. Tessier-Cloutier B, 2021, MODERN PATHOL, V34, P508, DOI 10.1038/s41379-020-00651-3
  73. Thali M, 2011, BIOCHEM SOC T, V39, P529, DOI 10.1042/BST0390529
  74. Thali M, 2009, CURR TOP MICROBIOL, V339, P85, DOI 10.1007/978-3-642-02175-6_5
  75. Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186
  76. van Spriel AB, 2010, MICROBES INFECT, V12, P106, DOI 10.1016/j.micinf.2009.11.001
  77. Vences-Catalan F, 2017, BIOCHEM SOC T, V45, P531, DOI 10.1042/BST20160478
  78. Woelber L, 2020, CURR OPIN OBSTET GYN, V32, P9, DOI 10.1097/GCO.0000000000000595
  79. Yang XH, 2001, CANCER RES, V61, P5284
  80. Yang YG, 2016, EXP HEMATOL, V44, P322, DOI 10.1016/j.exphem.2016.02.006
  81. Yuan N, 2020, CHIN J CHROMATOGR, V38, P36, DOI 10.3724/SP.J.1123.2019.06001
  82. Zeng TD, 2018, EUR REV MED PHARMACO, V22, P5928, DOI 10.26355/eurrev_201809_15922
  83. Zhang W, 2019, INT J ONCOL, V54, P1719, DOI 10.3892/ijo.2019.4742
  84. Zhang XA, 2003, CANCER RES, V63, P2665
  85. Zhang Y, 2020, EXP THER MED, V19, P755, DOI 10.3892/etm.2019.8244
  86. Zheng ZZ, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1279-0

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/58
Artigos e Materiais de Revistas Científicas - ODS/03